AMP EUROPE 2018 Achieving Dramatic Insights into Molecular and Precision

Rotterdam, The Netherlands April 30 – May 2, 2018 Skyline: #169602248 © brichuas/Shutterstock.com Skyline:

www.amp-europe-congress.com FINAL PROGRAM 1 4 Table of Contents About AMP 4

Congress Information

Get the latest knowledge Organizing Committee 6 in precision medicine and Gain practical insights that Contacts 6 Information Congress how it directly impacts you can use immediately. testing and treatment General Information A–Z 7 decisions. Scientifi c Program

Program Overview 12 Monday, April 30, 2018 13 Tuesday, May 1, 2018 19 Wednesday, May 2, 2018 25 c Program c 2 5 List of Invited Speakers 29 Speakers Biographies 30 Scientifi

Poster Exhibition Engage with thought Expand your network of leaders in the most talked- colleagues and business Poster Information 38 about areas of precision connections. Poster Listing 39 medicine. Poster Author Index 45

Industry Partners

Industry Symposia 51 List of Sponsors and Exhibitors 56 Industrial Exhibition Floor Plan 57 Poster Exhibition Poster 3 Exhibitor Descriptions 58

Spend 3 days in interactions that are really worth your time. Reasons to take part Industry Partners 5 AMP Europe 2018 | 3 About AMP

Who We Are The Association for Molecular (AMP) was founded in 1995 to provide structure and leadership to the emerging fi eld of molecular diagnostics. AMP’s 2,400+ members include individuals from academic and community medical centers, government, and industry;

Congress Information Congress including pathologist and doctoral scientist laboratory directors; basic and translational Information Congress scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fi elds in healthcare. AMP members infl uence policy and regulation around the globe, ultimately serving to advance innovation in the fi eld and protect patient access to high quality, appropriate testing. Congress Information Mission The Association for Molecular Pathology is a not-for-profi t scientifi c society that advances the clinical practice, science, and excellence of molecular and genomic laboratory medicine c Program c c Program c through education, innovation, and advocacy to enable highest quality . Scientifi How to Get Involved Scientifi AMP is the premier organization representing the needs and interests of the international molecular diagnostics community. AMP members receive a host of valuable benefi ts including access to our offi cial publication, The Journal of Molecular Diagnostics, discounted registration fees for AMP sponsored events, instant access to experts in the fi eld through AMP’s Members- Only community CHAMP, free access to many online learning materials, and a wide-variety of other resources and opportunities.

Join the global community of molecular pathology professionals and make AMP your professional home! To join visit: www.amp.org/join

Mary Steele Williams, MNA, MT(ASCP)SM

Poster Exhibition Poster Executive Director Exhibition Poster

Sara Hamilton, CMP Director of Meetings & Exhibits

Laurie Menser Director of Strategic Development

Industry Partners Industry Partners

4 | AMP Europe 2018 AMP Europe 2018 | 5 Committee & Advisors Contacts General Information A–Z

About Rotterdam Opening Hours Rotterdam welcomes you! A city of modern Monday, April 30 8:00 AM–7.45 PM architecture, bursting with its cosmopolitan Tuesday, May 1 7:30 AM–6:45 PM energy. Rotterdam’s dramatic skyline gives Wednesday, May 2 7:30 AM–5:30 PM © Ossip van Duivenbode

Congress Information Congress you a completely new perspective to The Information Congress Netherlands. Everywhere within the compact Congress Documents city center is easy to reach, so you can easily Registration fee for participants covers: explore and discover Rotterdam to get to admission to scientifi c sessions and industry know the city. An abundance of restaurants symposia, admission to the exhibition, lunch and cuisines, a choice of hotels; a culturally and coffee breaks. exciting mix of galleries, museums and theaters; an array of cafes and bars and a Congress Language renowned nightlife scene: Rotterdam gives The offi cial language of the congress is you endless possibilities at every street English. Simultaneous translation will not be c Program c c Program c corner! provided. Scientifi Act of God Congress Venue Scientifi It is mutually agreed that in the event of De Doelen International Congress Organizing Committee Scientifi c Organization total or partial cancellation of the congress Centre Rotterdam Andrea Ferreira-Gonzalez, PhD Association for Molecular Pathology (AMP) due to fi re, strike, natural disaster (either Willem Burger Kwartier Virginia Commonwealth University, USA 9650 Rockville Pike, Suite E205 threatened or actual), government regulations Kruisplein 40 Winand Dinjens, PhD Bethesda, MD 20814 or incidents not caused by the organizer, 3012 CC Rotterdam Erasmus MC, The Netherlands United States of America which would prevent its scheduled opening The Netherlands Rami Mahfouz, MD, MPH or continuance, the congress may be partially American University of Beirut Medical Center, Lebanon Legal Organizer (PCO) postponed or terminated as a whole. In this Currency Ernst-Jan Speel, PhD MCI Deutschland GmbH case, participants are not entitled to reclaim The Euro (€) is the offi cial currency in The Maastricht University Medical Center, The Netherlands MCI | Germany – Berlin refunds on no account. Participants are Netherlands. You can change money at Albrecht Stenzinger, MD Markgrafenstrasse 56 obliged to have civil liability insurance. banks and currency exchanges in airports

Poster Exhibition Poster Institute of Pathology, Germany 10117 Berlin, Germany or train stations. Classic credit cards are Exhibition Poster Certifi cate of Attendance Laura Tafe, MD T: +49 30 204590 American Express, MasterCard and Visa; Dartmouth Hitchcock Medical Center, USA F: +49 30 2045950 All registered participants will receive a Diners Club is rarely used, but accepted by [email protected] certifi cate of attendance. You will be able major hotels, petrol stations or large shops. www.amp-europe-congress.com to claim your certifi cate online. The link and Otherwise cash will be accepted. instructions will be sent to all the participants Registration after the congress. Electricity [email protected] In The Netherlands electricity is supplied at Cloakroom 230V, 50Hz, the power sockets are of type F Exhibition and Sponsoring The Cloakroom is located at the main (continental European standard). Adapters [email protected] entrance of Willem Burger Complex, in front are widely available in electronics stores. of the registration area. For confl ict disclosures of the Organizing Committee, please see amp-europe-congress.com Industry Partners Industry Partners

6 | AMP Europe 2018 AMP Europe 2018 | 7 General Information A–Z General Information A–Z

Helpful Phone Numbers all events. Registration of a participant entails Presenting Speakers have the barcode ready. Self-printing stations Taxi Rotterdam: +31 10 237 2018 acceptance of these conditions. Speaker are requested to hand are located directly in front of the registration +31 10 403 0303 in their presentations per e-mail desk. Fire Service: 112 Lost & Found ([email protected]) prior to the

Congress Information Congress Police: 112 A Lost & Found box will be placed at the congress. In case this has not been done Registration Desk Information Congress registration desk. please hand in the fi le at least one hour The registration desk is situated on the Insurance before your session at the technician’s desk ground fl oor, in the foyer of the Willem Burger The congress organizers do not accept any Name Badge at the back of the plenary room. Complex. liability for damages and/or loss of any kind The name badge will be the offi cial meeting which may be incurred by the congress. document and should be worn at all times Program Changes Opening Hours Participants or by any persons accompanying in order to gain entry to the meeting rooms The organizer reserves the right to make Monday, April 30 8:00 AM–6:30 PM them. Delegates participate in all events at and the exhibition halls. Admission to the changes if necessary. No full or partial Tuesday, May 1 7:30 AM–6:30 PM their risk. Participants are advised to take out conference will not be allowed without badge refunds are made to the attendees in the Wednesday, May 2 7:30 AM–5:30 PM insurances against loss, accidents or damage identifi cation. In case of lost or forgotten event of cancellations or other changes in c Program c c Program c that could occur during the congress. badges, an administration fee of € 20 will be the program. Please note that changes will Registration Fees Verbal agreements will not be binding unless charged. be posted at the registration desk and at the On-Site Scientifi they are confi rmed in writing. entrance of the session halls. Participants will Delegate, AMP Member € 500 Scientifi Parking Facilities be informed about the changes. Delegate, AMP Affi liate € 550 Internet Access There are several parking possibilities at the Society Member2 Free wireless internet access is available in congress center. Kruisplein/Schouwburgplein Public Transportation Delegate, Non-AMP Member € 580 the venue. Therefore a password is required. and Weena Qpark parking lots are in Depending on which method of transport Medical/Technical Assistants € 390 immediate proximity. you use, the names of stations below are the (MTA) Name: AMPEurope closest to the congress venue. The venue Students1 € 250 Password: Rotterdam2018 Photography, Audio, Video is approx. 5 minutes walking distance away Day Ticket4 € 200 and Mobile Phone Policy from every station. For detailed information: Please ensure the wireless connection on Audio, photo and video recording by any www.ret.nl/en Proof of current status needs to be provided your device is confi gured and your device is device (e.g. cameras, laptops, PDAs, mobile along with the registration.

correctly protected for wireless usage. No phones, watches) is strictly prohibited during Train Rotterdam Centraal Station 1 Student: A delegate who is an undergraduate, graduate or medical student. Poster Exhibition Poster technical support will be provided. all oral and poster sessions, unless prior Metro Centraal Station Exhibition Poster 2 AMP Affi liate Society: The German Society of Pathology, permission is obtained from the congress Tram Kruisplein with number 4, 7, 8, 20, The Hong Kong Society for Molecular Diagnostic Sciences, Liability Disclaimer organizer. Use of mobile phones is strictly 21, 23 and 25 The Korean Society for Laboratory Medicine, The Molecular The organizers cannot be held liable for prohibited during scientifi c sessions. Mobile Bus Centraal Station, bus numbers 33, Pathology Association of India, The Brazilian Society of and Laboratory Medicine (SBPC), any hindrance or disruption of congress phones must be switched off while attending 38, 40 and 44 The Italian Society of Pathology and Translational Medicine proceedings arising from political, social or sessions. (SIPMET) 4 without EACCME certifi cation economic events or any other unforeseen Registration incidents beyond their control. The organizers Poster Visits You can still register online and directly in will accept no liability for any personal injuries Odd Numbers Rotterdam. However, waiting can be eased, Smoking sustained or for loss or damage to property Tuesday, May 1 9:30 AM–10:15 AM if participants register online in advance. Smoking is strictly prohibited in the congress belonging to congress participants, either Pre-registered participants will receive a venue by law. during or as a result of the congress or during Even Numbers barcode which is required on-site in order to Wednesday, May 2 9:30 AM–10:15 AM print the badge. Therefore, it is essential to Industry Partners Industry Partners

8 | AMP Europe 2018 AMP Europe 2018 | 9 General Information A–Z

Social Program Time Zone The Get Together will take place in the Exhibit The Netherlands use Central European Time Hall on Monday, April 30, 6:15 PM. (CET), which is 1 hour ahead of Greenwich Mean Time (GMT+1). Congress Information Congress

Scientifi c Program Catering Main Entrance Way to 3rd Floor

c Program c Ground Floor Registration Poster Area

WC WC Scientifi

Catering

Entrance

Third Floor Poster Exhibition Poster

Willem Burger Hall

Catering Plenary

WC Entrance Plenary Catering Terrace Industry Partners

10 | AMP Europe 2018 Scientifi c Program Program Overview

Monday, April 30 Tuesday, May 1 Wednesday, May 2

8:00 AM– Registration Emerging Knowledge 9:00 AM 8:00 AM– 8:00 AM– Emerging Knowledge Biological Themes 9:30 AM 9:30 AM

Congress Information Congress Across Tumor Types Opening Remarks

Emerging Knowledge Coffee Break/ Coffee Break/ 9:00 AM– 9:30 AM– 9:30 AM– Recent Advances Odd Posters Even Posters 10:45 AM 10:15 AM 10:15 AM in Liquid Biopsies: Exhibition Hall Exhibition Hall Challenges and

MON Solutions 10:15 AM– 10:15 AM– Industry Symposium Industry Symposium Scientifi c Program Break 11:15 AM 11:15 AM Innovation Lab Monday, April 30 TUE 11:00 AM– Quality Control and Break Break 12:00 PM Assessment in c Program c Diagnostics Innovation Lab Innovation Lab Break 11:30 AM– 11:30 AM– WED Tumor Mutational Battle of 1:00 PM 1:00 PM

Scientifi Burden Bioinformatics Pipeline 12:15 PM– Industry Symposium 1:15 PM SP

1:00 PM– Lunch Break 1:00 PM– Lunch Break 1:15 PM– Lunch Break 2:00 PM Exhibition Hall 2:00 PM Exhibition Hall 2:15 PM Exhibition Hall

2:00 PM– 2:00 PM– Industry Symposium Industry Symposium 2:15 PM– 3:00 PM 3:00 PM Abstract Session #1 3:15 PM Break Break Break 3:15 PM– Abstract Session #2 Emerging Knowledge 3:30 PM– 4:15 PM Industry Symposium Clinically Signifi cant Poster Exhibition Poster 4:30 PM 3:15 PM– Big Data 5:00 PM

Coffee Break/Judging 4:15 PM– Innovation Lab 4:30 PM– Award Recognition & Poster Awards 5:15 PM Single Cell Sequencing 5:15 PM Closing Remarks Exhibition Hall

5:15 PM– Emerging Knowledge 5:15 PM– Innovation Lab 6:15 PM CRISPR 6:15 PM AMP NGS Guidelines

6:15 PM– Get Together 7:30 PM Exhibition Hall Industry Partners

12 | AMP Europe 2018 Scientifi c Program Monday, April 30, 2018 Scientifi c Program Monday, April 30, 2018

9:00 AM–9:15 AM Opening Remarks 11:00 AM–12:00 PM Innovation Lab Quality Control and Assessment in Cancer Diagnostics Andrea Ferreira-Gonzalez (Richmond, USA) Moderator: Rami Mahfouz (Beirut, Lebanon)

9:15 AM–10:45 AM Emerging Knowledge Session Description: This session will focus on quality control applications in cancer Congress Information Congress Information Congress Recent Advances in Liquid Biopsies: diagnostics with emphasis on cell free DNA with the emerging Challenges and Solutions need as more and more testing is relying on liquid biopsies. Internal and external quality assurance will be discussed as well Moderators: Andrea Ferreira-Gonzalez (Richmond, USA) the potential need for the availability of reference material that will Ernst-Jan Speel (Maastricht, The Netherlands) help in technical and diagnostic standardization. MON Session Description: This session will focus on how characterizing and monitoring MON Session Objectives: After attending this session, participants should be able to: tumor genomes with biological fl uid-base samples could achieve • Describe quality measures for cancer diagnostic testing signifi cant improvements in precision medicine. As tumors shed especially using cell free DNA. TUE parts of themselves into the circulation, analyses of circulating TUE • Learn about the existence of reference material, if any, for tumor cells, circulating tumor DNA, and tumor-derived exosomes, c Program c standardization of analytical testing and control assessment. Program c often referred to as “liquid biopsies”, may enable tumor • Realize the importance of profi ciency testing in cell free DNA genome characterization by minimally invasive means. As data WED WED analysis and interpretation. accumulates and test performance continues to improve, exciting Scientifi Scientifi applications are on the horizon for detection of disease faster, 11:00 AM–11:30 PM The Role of Reference Materials for Improving Quality diagnosis of disease earlier, and tracking of disease progression of Cancer Diagnostics SP SP and treatment response more effi ciently. The presenters in this Sandi Deans (Sheffield, UK) track bring together the most up-to-date information and current 11:30 AM–12:00 PM Improving the Profi ciency of Molecular Diagnostics state-of-the-fi eld for liquid biopsy as well as identifying current by External Quality Assessment (EQA) challenges and solutions. Michael Neumaier (Heidelberg, Germany) Session Objectives: After attending this session, participants should be able to: • Understand how to apply liquid biopsies for the advancement 12:15 PM–1:15 PM Industry Symposium of precision medicine. Please see page 51 for more information. • Evaluate the scope of clinical utility for liquid biopsies in cancer. • Understand the current challenges and possible solutions for the implantation of liquid biopsy in cancer management. 1:15 PM–2:15 PM Lunch Break

Poster Exhibition Poster Exhibition Hall Exhibition Poster 9:15 AM–10:00 AM CANCER-ID: European Network for Validation of Liquid Biopsy Tests Anna Babayan (Hamburg, Germany)

10:00 AM–10:45 AM Personalized Liquid Biopsy: Applications in Colorectal, Bladder, Breast, Lung and Beyond C. Jimmy Lin (San Carlos, USA) Industry Partners Industry Partners

14 | AMP Europe 2018 AMP Europe 2018 | 15 Scientifi c Program Monday, April 30, 2018 Scientifi c Program Monday, April 30, 2018

2:15 PM–3:15 PM Abstracts 5:15 PM–6:15 PM Emerging Knowledge Abstract Session #1 CRISPR

Moderator: Rami Mahfouz (Beirut, Lebanon) Moderators: Andrea Ferreira-Gonzalez (Richmond, USA) Ernst-Jan Speel (Maastricht, The Netherlands) Session Description: Oral Presentations from Selected abstracts Congress Information Congress Information Congress Session Description: RNA plays important and diverse roles in biology, but molecular Session Objectives: After attending this session, participants should be able to: tools to manipulate and measure RNA are limited. We • Analyze presentations of abstracts highlighted by the demonstrate that RNA-targeting CRISPR effector Cas13 can Organizing Committee as particularly signifi cant. be engineered for mammalian cell RNA knockdown, binding, • Evaluate the scientifi c merit and signifi cance of these selected and RNA editing. Cas13 can be heterologously expressed in MON studies through further discussion with the authors. MON mammalian and plant cells for targeted knockdown of either 2:15 PM–2:30 PM Comprehensive Molecular Characterization reporter or endogenous transcripts, targeted RNA binding for of Metastatic Cancer Using Whole-Genome Sequencing: transcript imaging, and programmable RNA editing. We also TUE a Dutch National Initiative combine Cas13a with isothermal amplifi cation to establish a TUE Paul Roepman (Amsterdam, The Netherlands) CRISPR-based diagnostic (CRISPR-Dx), providing rapid DNA c Program c or RNA detection with attomolar sensitivity and single-base Program c 2:30 PM–2:45 PM Multitumor Profi ling of Lymphocyte Activation 3 (LAG-3) mismatch specifi city. We use this Cas13a-based molecular WED WED and Association with Immune Cell detection platform, termed SHERLOCK, to detect specifi c Scientifi Scientifi Mustimbo Roberts (Princeton, USA) strains of Zika and Dengue virus, distinguish pathogenic bacteria, 2:45 PM–3:00 PM Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of- genotype human DNA, and identify cell-free tumor DNA . SP SP Function (LoF) Mutations in Patients With DNA Mismatch Our results establish CRISPR-Cas13 as a fl exible platform for RNA Repair-Defi cient/Microsatellite Instability-High (dMMR/ targeting with wide applicability for studying RNA or therapeutics. MSI-H) Metastatic Colorectal Cancer (mCRC) Treated Session Objectives: After attending this session, participants should be able to: With Nivolumab + Ipilimumab in CheckMate-142 • Describe how CRISPR technology can be modifi ed to Danielle Greenawalt (Princeton, USA) target RNA. 3:00 PM–3:15 PM QIAseq Digital Sequencing and Biomedical • Understand how CRSIPR technology could be used Workbench: Application to Liquid Biopsy in Bladder Cancer in the clinical laboratory. Francesco Lescai (Aarhus, Denmark) • Identify challenges for adoption of CRISPR technology for the clinical laboratory.

3:30 PM–4:30 PM Industry Symposium 5:15 PM–6:15 PM Harnessing RNA Targeting CRISPR Systems Poster Exhibition Poster Exhibition Poster Please see page 53 for more information. for Transcriptome Engineering and Human Health Omar Abudayyeh (Cambridge, USA)

4:30 PM–5:15 PM Coffee Break Exhibition Hall Judging Poster Awards 6:15 PM–7:15 PM Get Together Exhibition Hall Industry Partners Industry Partners

16 | AMP Europe 2018 AMP Europe 2018 | 17 ScientifiNotes c Program Monday, April 30, 2018 Congress Information Congress

MON Scientifi c Program Tuesday, May 1 TUE c Program c WED Scientifi SP Poster Exhibition Poster Industry Partners

18 | AMP Europe 2018 Scientifi c Program Tuesday, May 1, 2018 Scientifi c Program Tuesday, May 1, 2018

8:00 AM–9:30 AM Emerging Knowledge 11:30 AM–1:00 PM Innovation Lab Biological Themes Across Tumor Types Tumor Mutational Burden

Moderators: Winand Dinjens (Rotterdam, The Netherlands) Moderators: Winand Dinjens (Rotterdam, The Netherlands) Ernst-Jan Speel (Maastricht, The Netherlands) Albrecht Stenzinger (Heidelberg, Germany) Congress Information Congress Information Congress Session Description: Currently, molecular diagnostic DNA testing is guiding selection Session Description: Many challenges exist in assaying mutational burden in cancer of cancer patients who most likely will benefi t from targeted (TMB). This interactive session will explore how oncology can best treatment (precision medicine). This selection is largely based on use TMB and what diagnostic information is needed to predict the combination of a specifi c tumor type and the presence or response to . absence of specifi c mutations in the DNA. Information present MON Session Objectives: After attending this session, participants should be able to: MON in the transcriptome is largely ignored. In this session the clinical • Understand and describe the underlying biology and concept importance of similar DNA alterations in different tumor types as of tumor mutational burden (TMB). well as the use of a combination of both DNA and transcriptomic • Understand and describe the prerequisites and specifi c TUE analyses for response prediction will be addressed. TUE characteristics of assays measuring TMB. c Program c Session Objectives: After attending this session, participants should be able to: • Describe and interpret the clinical utility of TMB. Program c • Understand the value of DNA assessment for 11:30 AM–12:15 PM Microsatellite Instability in Relation to PDL1 Expression WED WED precision medicine across tumor types. and Tumor Mutational Burden in Cancer Patients Scientifi • Realize the advantages and shortcomings of DNA testing for Scientifi Ari M. VanderWalde (Germantown, USA) targeted treatment of cancer. SP • Describe how the combination of transcriptome and DNA 12:15 PM–1:00 PM Novel mRNA Vaccines for Personalized Cancer SP analysis may improve drug response prediction in cancer Immunotherapy patients. Alina Klein (Mainz, Germany) 8:00 AM–8:45 AM New Insights in the Pathogenesis of MSI Aysel Ahadova (Heidelberg, Germany) 1:00 PM–2:00 PM Lunch Break Exhibition Hall 8:45 AM–9:30 AM Next Generation Pathology Molecular Diagnostics: Combining DNA and RNA Analysis for Treatment Rene Bernards (Amsterdam, The Netherlands) 2:00 PM–3:00 PM Industry Symposium Please see page 53 for more information. 9:30 AM–10:15 AM Coffee Break Poster Exhibition Poster Exhibition Poster Exhibition Hall Visit Posters and Exhibit (Odd-numbered Posters Attended)

10:15 AM–11:15 AM Industry Symposium Please see page 53 for more information. Industry Partners Industry Partners

20 | AMP Europe 2018 AMP Europe 2018 | 21 Scientifi c Program Tuesday, May 1, 2018 Scientifi c Program Tuesday, May 1, 2018

3:15 PM–4:15 PM Abstracts 4:15 PM–5:15 PM Innovation Lab Abstract Session #2 Single Cell Sequencing

Moderator: Ernst-Jan Speel (Maastricht, The Netherlands) Moderators: Rami Mahfouz (Beirut, Lebanon) Albrecht Stenzinger (Heidelberg, Germany) Session Description: Oral Presentations from Selected abstracts. Congress Information Congress Information Congress Session Description: This session will explore technologies for Single Cell Sequencing Session Objectives: After attending this session, participants should be able to: using state-of-the-art NGS techniques and their applications in • Analyze presentations of abstracts highlighted by the understanding the function of individual cancer cells by providing a Organizing Committee as particularly signifi cant. higher resolution of cellular differences and functions in the proper • Evaluate the scientifi c merit and signifi cance of these selected corresponding microenvironment. MON studies through further discussion with the authors. MON Session Objectives: After attending this session, participants should be able to: 3:15 PM–3:30 PM Assessment of Circulating Tumor DNA in Patients With • Identify the variable technologies available for Single Cell Metastatic Colorectal Cancer Treated with Cetuximab Sequencing. TUE Monotherapy TUE • Compare the sensitivities of the variable techniques employed Lindsay Angus (Rotterdam, Netherlands) c Program c in Single Cell Sequencing. Program c 3:30 PM–3:45 PM External Quality Assessment Schemes for Gene Mutation • Estimate the importance of Single Cell Sequencing WED WED Testing in Oncology: Comparison of Performance between in diagnostic and research applications. Scientifi FFPE-Tissue and ctDNA in Plasma Scientifi 4:15 PM–5:15 PM Simultaneous Analysis of Cancer Clones and Immune Kaat Van Casteren (Leuven, Belgium) Microenvironments Through Single Cell RNA Sequencing SP SP 3:45 PM–4:00 PM Development and Characterization of Multigene Molecular Trevor Pugh (Toronto, Canada) Cell Slides as a Potential Fine Needle Aspirate (FNA)-Mimetic Specimen for Profi ciency Testing Sonika Saddar (Milpitas, USA)

4:00 PM–4:15 PM Use of Highly Multiplexed Reference Materials to Facilitate Validation of a Clinical NGS Tumor Fusion RNA Assay Dan Brudzewsky (Gaithersburg, USA) Poster Exhibition Poster Exhibition Poster Industry Partners Industry Partners

22 | AMP Europe 2018 AMP Europe 2018 | 23 Scientifi c Program Tuesday, May 1, 2018

5:15 PM–6:15 PM Innovation Lab AMP NGS Guidelines

Moderators: Andrea Ferreira-Gonzalez (Richmond, USA) Albrecht Stenzinger (Heidelberg, Germany) Congress Information Congress Session Description: In 2017, AMP partnered with various stakeholders to develop and publish two related published guideline manuscripts in The Journal for Molecular Diagnostics: 1) Guidelines for Validation of Next Generation Sequencing (NGS)-based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular

MON Pathology and College of American Pathologists and 2) Standards and Guidelines for the Interpretation and Reporting of Sequence Scientifi c Program Variants in Cancer: A Joint Consensus Recommendation of the Wednesday, May 2 TUE Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. This session c Program c will be a discussion of how the guidelines were developed and will provide practical case-based implementation advice for WED laboratories both currently performing somatic NGS and those Scientifi considering bringing these technologies into their laboratories.

SP Session Objectives: After attending this session, participants should be able to: • Discuss key points of the guideline for validation of NGS-based oncology tests. • Discuss key points of the guideline for the classifi cation, interpretation, and reporting of somatic sequence variants in NGS-based oncology panels. • Evaluate utility of these guidelines for development, validation, interpretation and reporting of the laboratory developed NGS tests using clinical case scenarios.

5:15 PM–6:15 PM Practice Guidelines for Validation, Interpretation and Reporting of NGS-Based Oncology Tests Poster Exhibition Poster Marina N. Nikiforova (Pittsburgh, USA) Industry Partners

24 | AMP Europe 2018 Scientifi c Program Wednesday, May 2, 2018 Scientifi c Program Wednesday, May 2, 2018

8:00 AM–9:30 AM Emerging Knowledge 11:30 AM–1:00 PM Innovation Lab Immunotherapies Battle of the Bioinformatics Pipeline

Moderator: Albrecht Stenzinger (Heidelberg, Germany) Moderators: Winand Dinjens (Rotterdam, The Netherlands) Albrecht Stenzinger (Heidelberg, Germany) Session Description: This session will provide an update on immunotherapies as well Congress Information Congress Information Congress as insights into tumor mutational burden (TMB) and microsatellite Session Description: Several companies’ NGS analysis pipelines will “wrestle” with data instability (MSI) as predictors of response to treatment with fi les that have been provided in advance. The obtained results checkpoint blockers. will be presented consecutively by the companies, after which a general discussion with involvement of participants will take place Session Objectives: After attending this session, participants should be able to: about the concordant and discrepant results. This session is MON • Understand the underlying concept and biology of MON expected to be both enjoyable and very informative. immunooncology (IO) and checkpoint blockade in particular. • Understand and describe the emerging role of genomic Session Objectives: After attending this session, participants should be able to: biomarkers predicting IO response. • Appreciate the complexity and diffi culty in NGS data analysis TUE TUE • Describe and interpret the design and characteristics of assays and interpretation. c Program c measuring TMB and MSI. • Appreciate that there is still no gold standard for NGS Program c data analysis and that most pipelines are to some extent 8:00 AM–8:45 AM Immunotherapies in Cancer, 21st Century Vaccines WED WED complementary. Carl Figdor (Nijmegen, The Netherlands) Scientifi • Take into consideration and implement these analysis Scientifi 8:45 AM–9:30 AM Tumor Mutational Burden-MSI uncertainties in data reporting for patient care. SP Hugo Horlings (Amsterdam, The Netherlands) SP Agilent Technologies Elias Hage (Amstelveen, The Netherlands) 9:30 AM–10:15 AM Coffee Break Qiagen Exhibition Hall Visit Posters and Exhibit (Even-numbered Posters Attended) Tim Bonnert (Manchester, UK)

Thermo Fisher Scientifi c 10:15 AM–11:15 AM Industry Symposium Greg Tyrelle (The Hague, The Netherlands) Please see page 55 for more information.

1:00 PM–2:00 PM Lunch Break Exhibition Hall Poster Exhibition Poster Exhibition Poster

2:00 PM–3:00 PM Industry Symposium Please see page 55 for more information. Industry Partners Industry Partners

26 | AMP Europe 2018 AMP Europe 2018 | 27

Scientifi c Program Wednesday, May 2, 2018 Scientifi c Program Invited Speakers

3:15 PM–4:45 PM Emerging Knowledge Clinically Signifi cant Big Data

Moderator: Laura Tafe (Lebanon, USA)

Session Description: This session will provide insight into how tomorrow’s healthcare Congress Information Congress Information Congress will depend on innovation in data analytics and .

Session Objectives: After attending this session, participants should be able to: • Describe opportunities for improving patient care using databases. MON • Identify resources that patient providers may utilize to learn MON more information about patients similar to their own. • Discuss how Big Data initiatives can advance biomarker discovery and translational medicine. TUE TUE 3:15 PM–4:00 PM Turning Little Data into Big Data: Data Science and the Omics c Program c c Program c Mark Hoffman (Missouri, USA) WED WED 4:00 PM–4:45 PM Oncology Research Information Exchange Network (ORIEN) Omar Abudayyeh, Alina Klein, PhD Scientifi William S. Dalton (Tampa, USA) Broad Institute, Cambridge, MA, USA BioNTech AG, Mainz, Germany Scientifi Aysel Ahadova, PhD C. Jimmy Lin, MD, PhD, MHS SP Heidelberg University, Heidelberg, Germany Natera, San Carlos, CA, USA SP 4:45 PM–5:00 PM Award Recognition & Closing Remarks Rene Bernards, PhD Michael Neumaier, MD Andrea Ferreira-Gonzalez (Richmond, USA) Netherlands Cancer Institute, Amsterdam, Heidelberg University, Heidelberg, Germany Rami Mahfouz (Beirut, Lebanon) The Netherlands Marina N. Nikiforova, MD Tim Bonnert, PhD University of Pittsburgh Medical Center, Pittsburgh, Qiagen, Manchester, UK PA, USA William S. Dalton, MD, PhD Klaus Pantel, MD M2Gen, Tampa, FL, USA University Medical Center Hamburg-Eppendorf (UKE), Sandi Deans, PhD Hamburg, Germany UK National External Quality Assessment Service Trevor Pugh, PhD

Poster Exhibition Poster (UK NEQAS), Sheffi eld, UK Princess Margaret Cancer Centre, University Health Exhibition Poster Carl Fidgor, PhD Network, Toronto, Canada Radboud University, Nijmegen, The Netherlands Greg Tyrelle, PhD Elias Hage, PhD Thermo Fisher Scientifi c, The Hague, The Netherlands Agilent Technologies, Amstelveen, The Netherlands Ari M. VanderWalde, MD, MPH Mark Hoffman, PhD West Cancer Center, Memphis, TN, USA The Children’s Mercy Hospital, Missouri, KS, USA Hugo Horlings, MD, PhD Netherlands Cancer Institute, Amsterdam, The Netherlands Industry Partners Industry Partners

28 | AMP Europe 2018 AMP Europe 2018 | 29

Scientifi c Program Speakers Biographies Scientifi c Program Speakers Biographies

Omar O. Abudayyeh, is René Bernards, PhD, his William S. Dalton, MD, Sandi Deans, PhD, is a an MD-PhD student in the laboratory at the PhD, is a medical Consultant Clinical Scientist Harvard-Massachusetts Netherlands Cancer oncologist and molecular and the Director of Institute of Technology Institute uses functional pharmacologist with an Genomics Quality

Congress Information Congress (MIT) Health Sciences and genomic approaches to interest in new drug Assessment (GenQA) part Information Congress Technology program. In the laboratory of fi nd vulnerabilities of cancers that can be discovery and mechanisms of drug of the UK National External Quality Feng Zhang at the Broad Institute of MIT and exploited therapeutically. Using the concept resistance. He is also the past President and Assessment Service (UK NEQAS) which is Harvard, Cambridge, Massachusetts, USA, of synthetic lethality, his laboratory searches CEO of the H. Lee Moffi tt Cancer Center in based in the Department of Laboratory his doctoral research focuses on the for combinations of that are lethal for Tampa, Florida, USA. He founded a health Medicine, Royal Infi rmary of Edinburgh. The MON discovery and characterization of novel cancer cells and for vulnerabilities of cancer information solutions company called EQA Scheme delivers assessment of MON CRISPR , such as Cpf1, C2c1 and cells of a defi ned genotype. As one example, M2Gen, and helped form ORIEN (Oncology molecular genetic testing, molecular Cas13a/C2c2, in bacteria for the purpose of his laboratory identifi ed the combination of a Research Information Exchange Network), a pathology testing, cytogenomic testing, TUE expanding the genome-editing toolbox and BRAF inhibitor and an EGFR inhibitor as data sharing alliance, comprised of seventeen newborn screening, prenatal diagnosis, TUE studying mammalian biology. His recent work effective for the treatment of BRAF mutant of the nation’s leading cancer centers. The preimplantation genetic diagnosis, variant c Program c c Program c has focused on using the RNA-targeting colon cancer. There are currently eleven mission of ORIEN is to accelerate cancer interpretation and a technical next generation WED WED CRISPR system Cas13 for building a clinical trials ongoing that test the effi cacy of discovery and deliver hope through sequencing scheme; ensuring high quality Scientifi transcriptome engineering toolbox for the cancer suggested by genetic collaborative learning and partnerships. Dr. genomic testing, end to end. Dr Deans is the Scientifi applications in diagnostics and therapeutics. screens from his laboratory. He also Dalton helped to develop an IRB approved National Laboratory and Scientifi c Lead within SP developed the fi rst clinically used gene protocol called Total Cancer Care (TCC) the NHS England 100,000 Genomes Project SP Aysel Ahadova, PhD, expression test for early breast cancer: designed to follow patients throughout their Genomic Implementation Unit and is working as a MammaPrint. lifetime, with patients consenting to provide collaborates closely with Genomics England postdoctoral fellow in the clinical, tissue, and molecular data to support to deliver high quality whole genome Department of Applied Tim Bonnert, PhD, heads precision medicine. All ORIEN members sequencing for both the rare diseases and Tumor Biology, University the Field Application agree to use the same TCC protocol and cancer programs. Dr Deans is a Honorary Hospital Heidelberg. She graduated from Scientist team for QIAGEN consent and have developed standards for Reader in Genomic Medicine at Edinburgh Azerbaijan Medical University in 2011 and Bioinformatics in EMEA data generation and sharing. The ORIEN University and a Senior Honorary Lecturer in came to Germany to work on her doctoral providing scientifi c support system is now being used to identify new the , University of St. thesis under the supervision of Magnus von and training to customers implementing cancer biomarkers to predict treatment Andrews.

Poster Exhibition Poster Knebel Doeberitz and Matthias Kloor. Her QIAGEN’s secondary analysis and tertiary response, molecular pathways to determine Exhibition Poster research mainly focuses on microsatellite interpretation solutions for NGS data. He is mechanisms of resistance, and development Carl Figdor, PhD, is a instability and its consequences for tumor based in the UK and joined QIAGEN in 2011 of evidence-based clinical decision support professor of development and progression. One particular after 6 years of leading the Applied Science tools at the point of care. He has over 200 and head of the topic of her research is colorectal group at Rosetta Biosoftware working with publications, and numerous patents in the department of Tumor carcinogenesis in Lynch syndrome. She transcriptomics, proteomics and genomics fi elds of drug discovery and computer/ Immunology at the works on revealing the molecular nature of applications. He received his Ph.D. in information networking. Radboudumc in Nijmegen. He obtained his Lynch syndrome-associated cancers in order phage display from the University of Masters degree in biology in 1979 from the to improve the therapeutic and preventive Cambridge and has over 12 years of University of Utrecht and his PhD degree in options for patients with hereditary cancer pharmaceutical research experience in medicine in 1982 from the University of predisposition. molecular biology, bioinformatics, and Amsterdam working at the Netherlands biomarker discovery using a range of Cancer Institute, where he got tenured in molecular profi ling techniques. 1985 and started his own research group. In Industry Partners Industry Partners

30 | AMP Europe 2018 AMP Europe 2018 | 31 Scientifi c Program Speakers Biographies Scientifi c Program Speakers Biographies

1992 Carl Figdor became Professor in Cell Elias Hage, PhD, is an Hugo Horlings, MD, PhD, interested in the development of personalized Biophysics at the University of Twente, and in application scientist at is a certifi ed surgical cancer vaccines and their clinical testing. 1994 he moved to the Radboud University Agilent Technologies where pathologist from the Medical Center in Nijmegen to start a new he provides pre- and Netherlands (2014). His Cheng-Ho Jimmy Lin,

Congress Information Congress department on Tumor Immunology. Here he post-sales functional and areas of expertise include MD, PhD, MHS, is the Information Congress initiated a large translational program technical support for all Agilent clinical breast, gynecological and molecular Chief Scientifi c Offi cer, exploiting the to fi ght cancer. software solutions. Before joining Agilent, he pathology. He has been awarded with a Oncology, at Natera. He Until 2010, he was scientifi c director of the obtained a PhD in virus genomics from the Translational research fellowship 2014–2018 comes from a long history RIMLS, Radboud Institute for Molecular Life Hanover Medical School where he worked from the Dutch Cancer Society to obtain as a pioneer in cancer genomics. Most MON Sciences, a research institute within the extensively with next generation sequencing training in clinical genomics – the application recently, he led the clinical genomics program MON domain of molecular mechanisms of disease technologies with a focus on establishing/ of large scale and high throughput genomic at the National Cancer Institute (NCI) at the that became internationally recognized during devising sample preparation methods and technologies in clinical settings. This will National Institutes of Health (NIH). Previously, TUE his leadership In 2006, he won the Spinoza bioinformatic techniques. maximize his ability as a pathologist to make at Johns Hopkins and Washington University TUE Prize, which is also known as “the Dutch a reality. Dr. Horlings in St. Louis, Dr. Lin was part of one of the fi rst c Program c c Program c Nobel Prize”, for his groundbreaking research Mark Hoffman, PhD, has pursued his training in the laboratories of clinical genomics labs in academia and led WED WED on the use of immune cells against cancer serves as the Chief Prof. Marc van de Vijver, Prof. Rene Bernards, the computational analyses of the fi rst ever Scientifi and for the translation of fundamental Research Information Prof David Huntsman and in collaboration exome sequencing studies in cancer, Scientifi research into patient care. His research offi cer for Children’s Mercy with several other experts at Stanford including breast, colorectal, pancreatic, SP interests focus on the molecular mechanisms Hospital (CMH) and the University and Rockefeller University USA. glioblastoma, medulloblastoma, and SP controlling presenting cells, in Children’s Research Institute. Dr. Hoffman Currently, he is starting his own research melanoma. He has published in top particular dendritic cells. Carl Figdor was one has delivered a TED talk on the “Envirome” group at the Netherlands Cancer Institute. academic journals, such as Science, Nature, of the fi rst to use dendritic cell in and won the iThermometer category in the The main research interest of the group is to and Cell, and has been an expert in national patients. He modifi ed dendritic cells to ‘teach’ Google wearable devices in healthcare defi ne genetic properties of breast and and international media outlets, such as New a patient’s immune system to recognize challenge in 2015. He is an inventor on ovarian carcinomas associated with York Times, Forbes, Bloomberg tumor cells. Major current research projects 19 issued patents and a member of the cancer- immune interactions and response to Businessweek, Washington Post, and the include the use of antigen loaded dendritic American Academy of Inventors. Dr. Hoffman immunotherapy. Financial Times. Dr. Lin holds an MHS in cell vaccines in the treatment of cancer is the PI on a CDC funded laboratory data Bioinformatics, a PhD in Cellular and patients and the generation of synthetic warehouse project. Prior to CMH, he served Alina Klein, PhD, is , and an MD from Johns

Poster Exhibition Poster dendritic cells. Professor Figdor received as VP for Research and Genomics at Cerner, currently a project manager Hopkins University as well dual majors in Exhibition Poster several prizes and honors including the Van where he led the development of their at BioNTech AG, Mainz, Cognitive Science and Molecular Biophysics Loghem Award (1999), Eijkman Medal (2000), molecular diagnostics solution, their clinical Germany. She received a and Biochemistry from Yale University. Spinoza prize (2006), Dutch Cancer trials capability, initiatives in and Master’s Degree in Foundation research award, the ERC their “big data” research efforts. Biomedical Science at the Philipps University Michael Neumaier, MD, Advanced Grant (2010) and the NWO Gravity of Marburg, Germany and a PhD in is a Clinical Chemist and Grant (2013). He is a member of the Biochemistry at the Goethe University Laboratory . He Academia Europaea and the Royal Dutch Frankfurt am Main, Germany. Her PhD work holds the chair for Clinical Academy of Arts and Sciences. He became a mostly focused on the cellular transfer of Chemistry of Heidelberg Knight in the Order of the Dutch Lion in 2012. fl uorescent probes and their observation via University in Germany. He is the vice Dean of live cell (super-resolution) microscopy. As a his Medical Faculty, the director of the project manager at BioNTech she is Institute for and member of the Executive Board at the University Hospital Industry Partners Industry Partners

32 | AMP Europe 2018 AMP Europe 2018 | 33 Scientifi c Program Speakers Biographies Scientifi c Program Speakers Biographies

Mannheim. Since 2009 he is a member of the adult and pediatric brain tumors (GlioSeq). Dr. biomedical and scientifi c journals (incl. NEJM, spends a portion of his time as a clinical German National Gene Diagnostics Nikiforova is a member of the Association for Lancet, Nature Journals, Cancer Cell, molecular geneticist within the University commission at the Robert-Koch-Institute, Molecular Pathology (AMP) where she served Science Translational Medicine, Cancer Health Network Laboratory Medicine Berlin, a long-standing member in the on Nominating committee, Program Discovery, PNAS, JCO, JNCI, Cancer Res.) Program.

Congress Information Congress advisory board of the German Medical Committee, and as a Chair of Solid Tumors and has been awarded the AACR Information Congress Council and chairman of the working group subdivision. During past two years, Dr. Outstanding Investigator Award 2010, Greg Tyrelle, PhD, is on Quality Management in Molecular Nikiforova served as a Chair of the Clinical German Cancer Award 2010, and ERC currently a Field Diagnostics. In the German Society for Practice Committee and on the Board of Advanced Investigator Grant 2011. Moreover, Bioinformatics Territory Clinical Chemistry and Laboratory Medicine Directors at AMP. Under her leadership, the Prof Pantel coordinates the European IMI Specialist with Thermo MON (DGKL), he acts – by appointment of the committee has developed analytical and consortium CANCER-ID (www.cancer-id.eu) Fisher Scientifi c, based in MON German Chamber of – as a clinical guidelines for NGS analysis and on blood-based “Liquid Biopsies” in lung and the Netherlands. He consults with Thermo director of the comprehensive national variant interpretation in cancer. She is also a breast cancer comprising 37 partner Fisher Scientifi c customers in the Europe, TUE external quality assessment (EQA) system run member of the Laboratory Practice institutions from academia, non-profi t Middle-East and Africa region to support their TUE by the Reference Institute for Bioanalytics Committee at the American Thyroid organizations and industry. next generation sequencing bioinformatics c Program c c Program c (RfB). Since 1998, he has initiated and Association (ATA). Dr. Nikiforova has needs. This includes implementation of WED WED organized various regular EQA programs for published over 150 peer-reviewed scientifi c Trevor Pugh, PhD, custom software, and data analysis pipelines Scientifi molecular diagnostics with up to 700 articles and fi ve book chapters, most of FACMG, is a cancer for novel assay development. He has worked Scientifi participating laboratories. Between 2014 and which in the area of molecular diagnostics of genomics researcher and across numerous application domains in SP 2016, Prof. Neumaier was President of cancer. clinical molecular geneticist genomics and sequencing from basic SP DGKL. Since 2018 he is President of the interested in understanding research to clinical diagnostics. Previously he EFLM. His main scientifi c interests are the Klaus Pantel, MD, is clonal shifts in cancer and non-cancerous cell has worked on pathobiochemistry of malignant disease, the Chairman of the Institute of populations in serial biopsies and circulating analysis and lead a team in Taiwan to design development and validation of methods for Tumour Biology at the tumor DNA collected during clinical trials, probes and annotate microarray data. the molecular diagnostics of cancer in bodily University Medical Center particularly immunotherapies. He is also fl uids and the molecular immunology of Hamburg-Eppendorf. The working to decipher subclonal genetic Ari M. VanderWalde, MD, innate immune cells expressing variable institute is part of the Centre of Experimental relationships amongst metastatic sites MPH, is Director of Clinical immunoreceptors. Medicine and the University Cancer Center suggestive of effective combination Research at West Cancer Hamburg (UCCH). Prof Pantel graduated in treatments, and to discover oncogenic Center and Associate Vice

Poster Exhibition Poster Marina N. Nikiforova, 1986 from Cologne University in Germany mechanisms underlying tumors of unknown Chancellor of Research at Exhibition Poster MD, FCAP, is Professor of and completed his thesis on mathematical etiology including breast, brain, University of Tennessee Health Science Pathology and Director of modelling of haematopoiesis in 1987. After neuroendocrine, gynecological, pediatric, and Center in Memphis, Tennessee. He received the Molecular & Genomic his postdoctoral period in the USA on other rare cancers. Dr. Pugh is appointed as his in 2005 from the Pathology Laboratory at the hematopoietic stem cell regulation (Wayne Scientist at the Princess Margaret Cancer University of Pennsylvania, obtained a University of Pittsburgh Medical Center State University, Detroit), he performed Centre and Assistant Professor in the Masters in Biomedical Ethics from the (UPMC). Dr. Nikiforova has a longstanding research at the Institute of Immunology, University of Toronto Department of Medical University of Pennsylvania and a Masters in clinical and research interests in genomics of University of Munich for 10 years. The Biophysics. He is Scientifi c Director of the Public Health from Harvard. He completed thyroid cancer and brain tumors and she has pioneer work of Prof Pantel in the fi eld of Princess Margaret Genomics Centre and training at UCLA, and led the development of a novel NGS-based cancer micrometastasis, circulating tumor Director of the Translational Genomics fellowship /oncology at City of tests for preoperative diagnosis of thyroid cells and circulating nucleic acids (ctDNA, Laboratory, a joint initiative with the Ontario Hope Comprehensive Cancer Center. He is cancer in FNA samples (ThyroSeq) and for microRNAs) is refl ected by more than 400 Institute for Cancer Research to enable board-certifi ed in Internal Medicine and diagnosis, prognostication and treatment of publications in excellent high ranking clinically-oriented genomics projects. He also Medical Oncology. At West Cancer Center, Industry Partners Industry Partners

34 | AMP Europe 2018 AMP Europe 2018 | 35 Scientifi c Program Speakers Biographies

Dr. VanderWalde serves as Chair of the Protocol Review Committee, co-chair of the Molecular Oncology Tumor Board, and Chair of the Cutaneous Malignancy Tumor Board.

Congress Information Congress He additionally serves as the Chair of the Clinical Trials Governance Board at University of Tennessee, the Medical Director of the Clinical Trial Network of Tennessee (CTN2), and the Executive Director of the Offi ce of

MON Clinical Research. Dr. VanderWalde has conducted multiple studies in immunotherapy Poster Exhibition and , including serving as PI

TUE for a number of immunotherapy and targeted therapy basket trials. He is a recipient of c Program c grants from the American Association of

WED Cancer Research, Stand Up to Cancer, and

Scientifi the Hope Foundation, among others. SP Poster Exhibition Poster Industry Partners

36 | AMP Europe 2018

Poster Exhibition Poster Exhibition

Poster Information First/Presenting Authors, Oral Presentations All posters are on display in the exhibit hall on including Award Multitumor Profi ling of Lymphocyte Activation Gene 3 (LAG-3) and Association the ground fl oor. Applicants, must attend their posters O11 with Immune Cell Phenotypes respectively on: M. Roberts

Congress Information Congress Award Applicants must attend their Tuesday, May 1, 9:30 AM – 10:15 AM Information Congress posters on: QIAseq Digital Sequencing and Biomedical Genomics Workbench: Odd-numbered posters attended O12 Application to Liquid Biopsy in Bladder Cancer Monday, April 30, 4:30 PM– 5:15 PM F. Lescai Interviews with members of the poster Wednesday, May 2, 9:30 AM – 10:15 AM Comprehensive Molecular Characterization of Metastatic Cancer Using reviewing committees Even-numbered posters attended O13 Whole-Genome Sequencing: a Dutch National Initiative Wednesday, May 2, at 4:45 PM Authors who have more than one even- or P. Roepman Awards Recognition & Closing Remarks odd-numbered poster may either ask another Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of-Function (LoF) Mutations author to attend their additional poster or in Patients With DNA Mismatch Repair-Defi cient/Microsatellite Instability- The Award Applicant posters will be attend it themselves during the other session. O14 High (dMMR/MSI-H) Metastatic Colorectal Cancer (mCRC) Treated With c Program c c Program c indentifi ed by a card mounted on the poster In the latter case, the author should place a Nivolumab + Ipilimumab in CheckMate-142 board. note on the poster board alerting attendees Z. Boyd Scientifi that they will attend the poster in the alternate Development and Characterization of Multigene Molecular Cytopathology Scientifi session. Cell Slides as a Potential Fine Needle Aspirate (FNA)-Mimetic Specimen O15 for Profi ciency Testing Poster Set-Up/Removal Q. Zheng Posters should be set-up Monday, April 30, External Quality Assessment Schemes for Gene Mutation Testing in Oncology: 10:00 AM – 3:30 PM. All posters must remain O16 Comparison of Performance between FFPE-Tissue and ctDNA in Plasma on display through 4:00 PM on Wednesday, K. Van Casteren May 2. Posters remaining past 4:30 PM will be removed and discarded. Please note that Use of Highly Multiplexed Reference Materials to Facilitate Validation of a Clinical O17 NGS Tumor Fusion RNA Assay poster-viewing is not eligible for Continuing D. Brudzewsky Education credit. Assessment of Circulating Tumor DNA in Patients with Metastatic Colorectal O18 Cancer Treated with Cetuximab Monotherapy Poster Exhibition Poster Exhibition Poster L. Angus Industry Partners Industry Partners

38 | AMP Europe 2018 AMP Europe 2018 | 39 Poster Exhibition Poster Exhibition

Poster Presentations MYD88 Mutation Detection by Ultra-Sensitive Droplet Digital PCR Reveals P13 High Potential of Aqueous Humor to Detect Vitreoretinal Lymphoma For Research Use Only? Regulatory and Quality Frameworks in Clinical NGS P01 L Hiemcke-Jiwa C. Nadeau Accurate Determination of DNA Concentration for Next Generation Sequencing Methylation Profi ling for Improved Tissue Diagnosis of CNS Tumors: Congress Information Congress P14 Applications Is Harder Than You Think Information Congress P02 the Utrecht Experience on >150 Cases N. Iley W. de Leng Using the Genereader NGS System to Identify Pathogenic Mutations Tumor Intrinsic Properties Associate With Differential Effects on CD8+ Tumor- P15 in Challenging Homopolymer Regions of BRCA1 and BRCA2 Infi ltrating Lymphocyte Density and Immune in Non-Small Cell P03 N. Dennison Lung Cancer (NSCLC) Samples C. Hedvat Evaluation of Customizable Circulating Tumor DNA (ctDNA) Reference Materials P16 with Multiple Assays Comprehensive Routine Diagnostic Screening to Identify Predictive Mutations D. Brudzevsky P04 and Copy Number Gains in FFPE Tumor Material A. Eijkelenboom Microsatellite Instability Analysis and NGS with Fragmented Sample Types c Program c P17 Program c S. Lewis Comparison of Comprehensive Solid Tumor DNA/RNA Panels for the Detection P05 of Small Nucleotide Variants, Copy Number Variants and Fusions Development of Well Characterized Breast, Lung, and Brain Cancer Copy Number Scientifi P. Sabatini P18 Variation Reference Materials Scientifi D. Brudzewsky Structural Variation Detection by Proximity Ligation from FFPE Tumor Tissue P06 C. Troll Detection of Microsatellite Instability in Circulating Cell-Free DNA from Colorectal P19 Cancer Patients Robust Measurement of Signal Transduction Pathway Activity in Cancer P. M. Ward P07 Using RNA Sequencing on Cells and FFPE tissue S. van den Bosch Patients Treated for Gastrointestinal Show Higher Abundance of Lactobacilli in Their Stool Compared to Non-Treated Patients through Application Number of Fusions Detected in FFPE Cancer Tissue Depends on RNA P20 of 16S rRNA Gene Sequencing P08 Isolation Method O. Youssef J. Doh, H. Wei Whole Exome Sequencing and Data Analysis of FFPE Tumor Samples to Find Incorporation of Gene Expression Profi ling for Cell-Of-Origin Determination P21 Clinically Relevant Alterations for Pediatric Cancer Treatment (Lymph2Cx Testing) Using Formalin-Fixed Paraffi n-Embedded Tissue Sections P09 E. Varkondi Poster Exhibition Poster in Routine Workfl ow for the Work-Up of Diffuse Large B-Cell Lymphoma Cases Exhibition Poster R. Robetorye Accurate FLT3-ITDs and CEBPA Variant Detection in Acute Myeloid Leukemia P22 by Anchored Multiplex PCR and Next Generation Sequencing Improved Methods for Next Generation Sequencing Library Cleanup N. Nair P10 and Size Selection C. Cowles Using the GeneReader NGS System and QIAact Lung All-in-One Assay to Detect P23 Complex Mutations and Fusions TP53 Mutations in Circulating Cell-Free DNA as Longitudinal Biomarker S. Hughes P11 for High-Grade Serous Ovarian Cancer S. R. Vitale Using the GeneReader NGS System and QIAact Myeloid DNA UMI Panel P24 to Detect Complex Mutations in Myeloid Leukemia Validation of the GeneReader NGS System and Its Workfl ow for BRCA 1/2 O. Biglia P12 Sequencing Test E. Lee Industry Partners Industry Partners

40 | AMP Europe 2018 AMP Europe 2018 | 41 Poster Exhibition Poster Exhibition

Cardiovascular Diseases (CVDs) Patients with Hypertrophic Epicardial Adipose P36 Withdrawn P25 Tissue (EAT) Has a Microbiome Core Associated to Innate Immunity Activation Evaluation of the Luminex® ARIES® HSV1&2 Assay for the Detection E. Vianello P37 and Differentiation of HSV-1 and HSV-2 in Cerebrospinal Fluid Samples Performance of Different Specimen Types and Quantitation on Ampliseq Cancer T. Her

Congress Information Congress P26 Hotspot Panel V2.0 Kit over Three Years Information Congress An Open-Source End-To-End NGS Clinical Data Management System C. Stefaniuk P38 Used to Improve Variant Reporting and Data Mining Detection of EGFR Mutations in Circulating Cell-Free DNA (cfDNA) from Plasma S. Kadri Samples of Patients with Non-Small Cell Lung Cancer Using the Oncomine Lung P27 Evaluation and Application of RNA Fusion Gene Panel for the Patients cfDNA Assay P39 with Acute Leukemia S. Anand B. Kim The Use of a Hybridisation-Based Enrichment Approach to Achieve the Complete Next Generation Sequencing on Ion Proton for Mutation Detection Coverage by Next-Generation Sequencing (NGS) of Diffi cult to Sequence P28 in Brain Tumors: Development of Molecular Pathology Assays in the Kingdom (CALR, CEBPA, FLT3) Associated with Myeloid Disorders P40 of Saudi Arabia c Program c L. Georgieva Program c M. M. Taher Speeding Clinical Reporting of Targeted Sequencing of Cancer Gene-Panels The Challenge of Whole Genome Sequencing in Mainstream Cancer Testing through Seamless Integration of Data Quality Control, Mutation Genomic P41 Scientifi P29 Z. Deans Scientifi and Clinical Annotations, and Drug Sensitivity Options F. De La Vega Detection of A Rare Defi cient Allele of Alpha-1 Antitrypsin, M(Procida), P42 Using Melt Curve Technology Variant Analysis for the F and I Alleles Performance Evaluation of LymphoTrack Clonality Assays on Ion PGM C. Stefaniuk P30 and Ion S5 Platforms Y. Huang Detection of 17 Targets in a Single PCR Tube by a Novel Probe System P43 Combining Melting Curves and Taqman Probes Single-Step IGHV Next Generation Sequencing Detects Clonality S. Echwald P31 and Somatic Hypermutation in Lymphoid Malignancies P. P. PiccalugaI Implementation of the GeneReader NGS System in a Molecular P44 Pathology Laboratory An Engineered DNA Ligase for Effi cient Conversion of Input DNA A. Boesl P32 During NGS Library Preparation M. Miller Anchored Multiplex PCR Enables Sensitive NGS-Based Mutation Detection

Poster Exhibition Poster P45 in the Context of Large Primer Panels Exhibition Poster Comprehensive Analysis of Genetic Variations in Patients V. Johnson P33 with Acute Lymphoblastic Leukemia B. Kim Analytical Validation of Digital Spatial Profi ling – a Novel Approach for Multiplexed P46 Characterization of Distribution and Abundance in FFPE Tissue Sections Using GeneReader NGS System to Identify Mutations in BRCA 1/2 Genes D. Hinerfeld P34 in Matched FFPE and Blood Samples V. Kapoor How Variabilities in Tumor Liquid Biopsy Workfl ows Can Be Tackled P47 with cfDNA Reference Standards A Comparative Study of PD-L1 Protein Expression Using the Ventana SP263 K. Wilczynska Diagnostic Assay and PD-L1 Mrna Expression Using Rnascope in Formalin Fixed P35 Paraffi n Embedded Samples of Non-Small Cell Lung Cancer (NSCLC), Head P48 Withdrawn and Neck Squamous Cell Carcinoma (HNSCC) and Urothelial Carcinoma (UC) D. Duncan Industry Partners Industry Partners

42 | AMP Europe 2018 AMP Europe 2018 | 43

Poster Exhibition Poster Exhibition Index

Comprehensive Sequencing Analysis Performed Routinely on Clinical Samples Abduljaleel Z. P40, P59 Campan M. P19 P49 Can Provide Unexpected and Clinically Signifi cant Findings: a Case Example Ahmed Z. P56 Carpelan-Holmström M. P20 J. Nakitandwe Al-Allaf F.A. P40, P59 Caulfi eld M. P41 Al-Khalidi H.M. P40, P59 Cerkl P. P44 ISO Accreditation of a Complete Next Generation (NGS) Sequencing Workfl ow Alyami S.H. P40, P59 Chan J. P28, P51

Congress Information Congress P50 for BRCA1/2 Analysis Anand S. P27 Charifi F. P24 Information Congress S. Marchini Anekella B. P16, P18 Cheng Y.W. P26 Angus L. O18 Choi J.-R. P33, P39 The Analysis of FFPE Samples by Next-Generation Sequencing (NGS) Aronica E P02 Chowdhury S.S. P58 P51 of Key Genes for Research into Breast and Ovarian Cancers Arora N. P58 Chun S. P12 J. Chan Arzuffi P. P23 Clay M.R. P49 Allele-Specifi c Real Time Polymerase Chain Reaction (PCR) Versus Peptide Athar M. P40, P59 Clement O. P16, P18 Nucleic Acid Clamping for Low Copy Epidermal (EGFR) Atmodimedjo P. P11 Corsi Romanelli M.M. P25 P52 Mutation Detection in Liquid Biopsy Samples Azzato E.M. P49 Costa H. P06 Bakker R. P07 Cowles C. P10 P. M. Das Ballabio S. P50 Craig C. P41 c Program c c Program c Rapid, Multi-Gene Mutation Detection Panel for Metastatic Colorectal Cancer Banerjee S. P58 Craparotta I. P50 A. Stanco Baniyaseen K.A. P59 D’Incalci M. P50 Barker C. P35 Dairi G.S. P40, P59 Scientifi Clinicopathological Features of Colorectal Carcinoma in Ukrainian Patients Scientifi Barker K. P46 Das P.M. P52 P54 with MSI-H and MSS Status Barzi A. P19 Davison V. P14 D. Shapochka Baskerville S. P32 De Boer J. P13 Rational “Error Elimination” Approach to Evaluating Molecular Barcodes Beaufort C. P11 De Grandi R. P25 Containing Next-Generation Sequencing Data Identifi es Low-Frequency Mutations Beechem J. P46 De Groot-Mijnes J. P13 P55 in Hematologic Malignancies Beltrame L. P50 De La Vega F. P29 S. Mallampati Benhamed S. P38 De Leng W. P02 Berns E.M.J.J. P11 De Regt B. P07 Clinical Correlation between Translocation Variant and Outcome in Philadelphia Bessette M. P22 De Voijs C. P02 Chromosome-Positive Chronic Myeloid Leukemia and Acute Lymphoblastic Biglia O. P24 De Vos F. P02 P56 Leukemia Patients Blanchette M. P06 De Vries A. P44 Z. Ahmed Blankfard M. P30 De Weger R. P13 Blatter A. P10 Deans Z.C. P14 P57 Withdrawn Poster Exhibition Poster Blood J. P23 Deans Z. P41 Exhibition Poster Molecular Profi ling in Colorectal Carcinoma: a Tertiary Centre Experience Boere I.A. P11 Dellas N. P32 P58 from Eastern India Boesl A. P44 Denhart M. P10 P. Gupta Bogari N.M. P40, P59 Dennis L. P46 Böhling T. P20 Dennison N. P15, P34 Identifi cation of a Novel ATM Missense Mutation by Next Generation Sequencing Bona A. P24 Deri J. P21 P59 in Choroid Plexus Papilloma Bosler D. P42 Desai K. P03 M. M. Taher Bouazzaoui A.L. P40, P59 Dickens J. P16, P18 Bouzaffour A. P30 Dimastrogiovanni D. P27 Brudzewsky D. O17, P16, P18 Dinjens W.N.M. P11 Burke A. P15, P34 Doh J. P08 Burton A. P15, P23, P34 Donati F. P50 Bustamante C P06 Dozio E. P25 Butler C. P27 Drago L. P25 Industry Partners Industry Partners Butler M.G. P16 Du L. P19

44 | AMP Europe 2018 AMP Europe 2018 | 45 Poster Exhibition Index Poster Exhibition Index

Dubbink H.J. P11 Henderon S. P41 Kunder C. P06 Nair N. P22 Dubeau L. P19 Hendriks-Cornelissen S.J. P04 Kusters B. P02 Naiyachit Y. P47 Duncan D. P35 Her T. P37 Lafi S. P24 Nakitandwe J. P49 Duose D. P55 Herreboudt A. P47 Lahti L. P20 Nederlof P.M. P04 Dyson R. P15, P34 Hiemcke-Jiwa L. P13 Laloux V. P24 Nemes C. P44

Congress Information Congress Echwald S. P43 Hill S. P14, P41 Larsen J. P24 Neugebauer A P44 Information Congress Eckert S. P51 Hinerfeld D. P46 Lauber J P15, P23, P24 Newman S. P49 Edwards R. O11, P03 Hing S. P41 Lee E. P12 Nierken S. P13 Ehsan H. P20 Honing H. P10, P17 Lee S.-T P33, P39 Niu N. P38 Eijkelenboom A. P04 Hook B. P17 Lee W. P12 O’Neal T. P49 El-Bjeirami W.M. P40, P59 Horejsh D. P10 Leguit R. P13 Oester B. P15, P34 Elgart D. P32 Huang C. P18 Lescai, F. O12 Offner F. P44 Ellison D. P49 Huang Y. P30, P31 Lesniak J. P03 Oostdik K. P17 Ely S. P03 Hughes S. P15, P23, P24, P34 Lewis S. P17 Ossewaarde-van Norel J. P13 Ewing-Graham P.C. P11 Huibers M. P13 Licon A. P22, P45 Pal B. P58 Fabian O. P21 Hutt K. P30, P31 Ligtenberg M.J. P04 Palhazi B. P21 c Program c c Program c Falcioni M. P29 Iley N. P14 Litterst C. P52 Pandya D. P03 Farkas D. P42 Jakubowski M. P26 Liu H. P27 Panganiban J. P30, P31 Farkas Z. P21 Jansen M. P11 Long T. P19 Pappo A. P49 Scientifi Scientifi Feitsma H. P07 Jastania R.A. P40, P59 Lorinczi O. P21 Paracchini L. P50 Fowler T. P41 Joecker A. P15 Lowe D.R. P18 Park N. P12 French M. P03 Johnson L. P22 Lu W. P27 Patil S.A. P38 Ganbat J. P06 Johnson V. P45 Lueerssen D. P15, P23, P24, P34 Petak I. P21 Ganguly S. P58 Jones A. P27 Luthra R. P55 Pettersson J. P19 Garami M. P21 Jones L. P41 Mah M. P05 Pfi sterer M. P44 Garlick R.K. P16 Kadri S. P38 Mallampati S. P55 PiccalugaI P.P. P31 Gazzola A. P31 Kamal R. P29 Mallath M.D. P58 Pileggi S. P50 Georgieva L. P28, P51 Kamel-Reid S. P05 Mannarino L. P50 Plagov A. P38 Ghosh J. P58 Kanagal-Shamanna R. P55 Mannu C. P31 Plasschaert S. P02 Gilligan D. P27 Kang W. P38 Marchant K. P42 Potikyan G. P53 Glinsmann-Gibson B. P09 Kapoor V P15, P34 Marchini S. P50 Powers M. P06 Gomes S. P32 Karla T. P20 Matharu B. P27 Priesterbach L. P02

Poster Exhibition Poster Green R. P06 Kastner-van Raaij A.W. P04 McDonnell K. P42 Puolakkainen P. P20 Exhibition Poster Griffi n L. P22, P45 Kim B. P33, P39 Mehrotra M. P55 Putnam N. P06 Groenendijk F.H. P11 Kiruluta E. P29 Merritt C. P46 Ramsower C. P09 Gupta P. P58 Kiss E. P21 Metz H. P46 Rautelin H. P20 Gupta V. P23, P24 Klass M. P31 Miller J.E. P30 Reese M. P29 Haimes J. P22 Knox C. P10, P17 Miller J. P31 Revay C. P42 Hamblin A. P41 Knuutila S. P20 Miller M. P32 Rice B. P06 Harden S. P27 Kokkola A. P20 Min W.-K. P12 Rimsza L. P09 Harmon M. P55 Konigshofer Y. P16, P18 Mishra D.K. P58 Ritterhouse L.L. P38 Hartley P. P06 Kopetz, S. O14 Moore K. P22, P45 Robb A. P15, P34 Hassan A.A. P40, P59 Koskensalo S. P20 Moorhead J. P41 Robe P. P02 Hedvat C P03 Kroeze L. P04 Mularo F. P42 Robetorye R. P09 Hegedus C. P21 Kudlow B. P22 Murugaesu N. P41 Roepman, P. O13 Helleman J. P11 Kuijpers S. P07 Nadeau C. P01 Roholl F. P13 Industry Partners Industry Partners Helmijr J. P11 Kuiper J. P13 Nageeti T.H. P40, P59 Roy P. P58

46 | AMP Europe 2018 AMP Europe 2018 | 47 Poster Exhibition Index

Rusch M. P49 Turnbull C. P41 Sabatini P. P05 Uddin E. P28 Saeed M.I. P40, P59 Urh M. P10 Saha K. P58 Valerie K P40, P59 Santra P. P58 Van Brussel A. P07

Congress Information Congress Sarhadi V. P20 Van Casteren, K. O16 Schauser L. P15, P23, P24, P34 Van den Bosch S. P07 Schneider J. P44 Van der Veken L. P02 Schoots M. P02 Van Doorn H.C. P11 Schutzbank T. P37 Van Driel M. P07 Schuuring E. P04 Van Hemert F. P07 Schwab R. P21 Van Kempen L.C. P04 Scorer P P35 Van Marion R. P11 Industry Partners Scott M. P27, P35 Varkondi E. P21 Segal J.P. P38 Verhaegh W. P07 Selezniov O. P54 Verrissimo T P27 c Program c Shapochka D. P54 Vianello E P25 Shapochka T. P54 Viduya J. P32 Shurtleff S.A. P49 Vinarkar S. P58 Scientifi Siddiqui S. P06 Vitale S.R. P11 Snijders T. P02 Von Deimling A. P02 Speight G. P28, P51 Vroom J. P32 Srinivasan S. P03 Vykhrieva M P54 Stanco A. P53 Walker J. P35 Stefaniuk C. P26, P42 Walters R P22, P45 Steger C. P44 Wang X.-T. P03 Stockley T. P05 Wanjari P. P38 Stoller J. P42 Ward P.M. P19 Strengman E. P02 Webster P. P46 Sulaieva O. P54 Wei H. P08 Sun X. P55 Wendel Spiczka A. P09 Surmann E.-M. P47 Wesseling P. P02

Poster Exhibition Poster Szabo P. P03 Wickenden J P47 Taher M.M. P40, P59 Wilczynska K. P47 Ten Dam-van Loon N. P13 Wistuba I. P55 Ter Elst A. P04 Wong A. P05 Thiagarajah M. P05 Yang W. P52 Thoegerson L. P15, P34 Yip T. P09 Tikkanen M. P20 Youssef O. P20 Tops B.J.J. P02, P04 Zalles S. P55 Toscano M. P25 Zehnder J. P06 Toth N. P21 Zhang J. P49 Tran H.B. P52 Zhang T. P05 Troll C. P06 Zheng Q. O15 Tsai J. P52 Zimmerman J. P03 Ttavas K. P15, P34

Industry Partners Turkina A. P54

48 | AMP Europe 2018

Industry Partners Industry Symposia

Monday, April 30, 2018

12:15 PM–1:15 PM Industry Symposium Agilent Technologies: NGS in Pathology: Challenges, Considerations and Solutions

When you SEEK Moderator: Harpinder Mundi (London, UK) Information Congress 12:15 PM–12:45 PM NGS in Pathology – Challenges, Considerations and Solutions exquisite sensitivity Wouter Bossuyt (Niels, Belgium) 12:45 PM–1:15 PM Whole-Exome Sequencing on Formalin-Fixed Paraffi n- from a liquid biopsy Embedded Tumour Samples Richarda de Voer (Breda, The Netherlands)

3:30 PM–4:30 PM Industry Symposium

Roche Diagnostics: Next-Generation Sequencing With Program c AVENIO ctDNA Analysis Kits: Technological and Scientifi c Overview Scientifi Moderator: John Palma (Pleasanton, USA) Look to Agena’s UltraSEEK™ Technology 3:30 PM–3:35 PM Welcome John Palma (Pleasanton, USA)

3:35 PM–3:45 PM Technological Overview of AVENO ctDNA Analysis Kits Marcus Droege (Rotkreuz, Switzerland)

Identify clinically informative 3:45 PM–4:05 PM Use of ctDNA NGS for Monitoring and Surveillance Join our Satellite Symposium in Oncology Research mutations, including indels from John Palma (Pleasanton, USA) BRAF, EGFR, ERBB2, KRAS, NRAS, at AMP Europe 2018 and PIK3CA. 4:05 PM–4:30 PM Application of Circulating Tumor DNA in the Context of Non- MAY 2, 10.15AM | WILLEM BURGER HALL Small Cell Lung Cancer Detect over 70 mutations at as low Steffen Dietz (Heidelberg, Germany) Why Liquid Biopsy is important in clinical Exhibition Poster as 0.1% variant allele frequency routine - Prof. Ron van Schaik, Dept. Clinical from a single blood draw. Chemistry, Erasmus MC Rotterdam

Generate results in as fast as a day ALK-EML4 fusions in ctDNA of lung at a fraction of the cost of NGS. cancer patients in the clinical practice - Prof. Antoinette Lemoine, APHP Hôpital Universitaires Paris-Sud-Villejuif

VISIT US AT BOOTH # T10

For more information visit agenabio.com

UltraSEEK is for Research Use Only. Not for use in diagnostic procedures. Industry Partners AMP Europe 2018 | 51 Industry Partners Industry Symposia Industry Partners Industry Symposia

Tuesday, May 1, 2018

10:15 AM–11:15 AM Industry Symposium Illumina: The Pathway Towards Comprehensive Tumour Profi ling and the Evolution of TMB into Clinical Research

Congress Information Congress Moderator: Ilja Stap (Cambridge, UK) Information Congress

10:15 AM–10:20 AM Introduction Ilja Stap (Cambridge, UK)

10:20 AM–10:45 AM Evaluation of the TruSight™ Tumor 170 (TST170) Assay and its Value in Clinical Research Carina Heydt (Cologne, Germany)

10:45 AM–11:10 AM Predictive Genetic Biomarkers for Checkpoint Blockers Albrecht Stenzinger (Heidelberg, Germany) c Program c c Program c 11:10 AM–11:15 AM Summary Ilja Stap (Cambridge, UK) Scientifi Scientifi

2:00 PM–3:00 PM Industry Symposium NanoString Technologies: Powering Precision Oncology Research With 3D Biology™ Technology: High Plex Multi- Analyte Profi ling on FFPE With Spatial Resolution

2:00 PM–2:30 PM Powering Precision Oncology Research With 3D Biology™ Technology: High Plex Multi-Analyte Profi ling on FFPE With Spatial Resolution Joseph Becheem (Seattle, USA)

2:30 PM–3:00 PM RNA Profi ling of Gene Fusion Events in Lung Cancer and Sarcomas Using NanoString nCounter Platform Leon van Kempen (Groningen, The Netherlands) Poster Exhibition Poster Exhibition Poster

500 Cummings Center, Suite 4550 | Beverly, MA 01915 USA | [email protected] | 800.215.1824 | LexaGene.com | 0TCQB:LXXGF | TSX.V: LXG Industry Partners Industry Partners

52 | AMP Europe 2018 AMP Europe 2018 | 53 Industry Partners Industry Symposia

Wednesday, May 2, 2018

10:15 AM–11:15 AM Industry Symposium Agena Bioscience

10:15 AM–10:45 AM Why Liquid Biopsy is Important in Clinical Routine … &VI]SYSǺIVMRK Ron van Schaik (Rotterdam, The Netherlands) Information Congress (ERGIV5VIGMWMSR2IHMGMRI$ 10:45 AM–11:15 AM ALK-EML4 Fusions in ctDNA of Lung Cancer Patients in the Clinical Practice Antoinette Lemoine (Paris, France) We are happy to provide you with a highly comprehensive cancer report to guide patient treatment 2:00 PM–3:00 PM Industry Symposium QIAGEN: The Power of Precision Medicine in Breast and Overian Cancer

Moderator Kai Wesche (Hilden, Germany) Program c

2:05 PM–2:20 PM PITX2 DNA Methylation, a Novel Validated Marker in High-Risk Breast Cancer Scientifi Olaf G. Wilhelm (Munich, Germany) We combine your Genomic NGS Data with molecular pathology, IHC test results 2:20 PM–2:35 PM Identifi cation of BRCA1/2 Pathogenic Variants in Both Solid and clinical data, leading your oncologists Tumor Samples and Liquid Biopsies by GeneReader NGS through the best treatment options. Sergio Marchini (Milano, Italy)

Please visit us at our booth number G10 2:35 PM–2:50 PM Standardized Interpretation and Actionable Reporting during AMP Europe 2018 in Rotterdam to of Challenging BRCA Mutations discover more details about OncoKDM. Anika Joecker (Hilden, Germany) Beate Litzenburger (Hilden, Germany)

2:50 PM–3:00 PM Question and Answer Discussion Kai Wesche (Hilden, Germany) The most advanced interpretation solution Poster Exhibition Poster for cancer management combining multiple pathology data and giving you access to

600 30 000 3 000 20 000 228 Drugs Variants Clinical trials Analysis Cancers

1 Rue Louis Breguet +32 (0)71 18 35 00 www.oncokdm.com www.oncodna.com B-6041 Gosselies, Belgium Industry Partners

AMP Europe 2018 | 55 Industry Partners List of Sponsors and Exhibitors Industry Partners Industrial Exhibition Floor Plan

The Industrial Exhibition will take place on the Ground and Third Floor. Ground Floor

Opening Hours

Monday, April 30, 2018 8:30 AM–7:30 PM G19 Catering

Congress Information Congress Tuesday, May 1, 2018 9:00 AM–3:30 PM Main Entrance Information Congress Way to Wednesday, May 2, 2018 9:00 AM–5:00 PM 3rd Floor G1 G18

List of Exhibitors and Sponsors G17 Poster Area Registration

G13 G14 G15 G16 Exhibitor/Sponsor Booth Exhibitor/Sponsor Booth G12 G11 G10 G9 WC WC Agena Bioscience T10 New England Biolabs GmbH T4

Agilent Technologies T13 OncoDNA S.A. G10 G3 G4 G8 Catering

ArcherDX G12 Oxford Gene Technology (OGT) T14 c Program c c Program c Beckman Coulter T15+16 Oxford Nanopore T5 Technologies Ltd. Bio-Rad Laboratories B.V. G14 Scientifi Scientifi Philips Molecular Pathway Dx T8 Bristol-Myers Squibb G17 Third Floor Promega Corporation T12 Bruker Daltonics G16 QIAGEN T19 CELEMICS G4 Roche Diagnostics T3 Covaris T2 Entrance SeraCare Life Sciences G11

Diatech Pharmacogenetics – T1 SOPHiA GENETICS T1

Epigenomics G3 T2 STEMCELL Technologies T7 ExScale Biospecimen G13 T9 Solutions AB Stilla Technologies G18 T3 Willem Burger Hall

Poster Exhibition Poster GC biotech BV T18 STRATEC Molecular G15 Exhibition Poster Catering GeneFirst Ltd T17 Thermo Fisher Scientifi c T6 T4

Illumina T9 Twist Bioscience G19

LexaGene G9 XIAMEN SPACEGEN CO., LTD. G8 T5

MRC-Holland T11 T6 WC T10 Entrance NanoString Technologies G1 Plenary T7 T11 Catering T19 Terrace T8 T12 T13 T14 T15+16 T17 T18 Industry Partners Industry Partners

56 | AMP Europe 2018 AMP Europe 2018 | 57 Industry Partners Exhibitor Description Industry Partners Exhibitor Description

Agena Bioscience ArcherDX Bio-Rad Bruker Daltonics Booth No. T10 Booth No. G12 Laboratories B.V. Booth No. G16 Germany USA Booth No. G14 Germany +49 40 899676 59 +1 877 771 1093 The Netherlands +49 (421)2205-0

Congress Information Congress [email protected] [email protected] +31 (0) 318 540 666 [email protected] Information Congress www.agenabio.com www.archerdx.com [email protected] www.bruker.com www.discover.bio-rad.com We Empower Precision Medicine Archer® target enrichment assays utilize Over 50 years, Bruker has enabled scientists Agena Bioscience is advancing genomics in Anchored Multiplexed PCR (AMP™) Bio-Rad Laboratories is a world leader to make breakthrough discoveries and healthcare and precision medicine. Our highly chemistry to generate highly enriched in providing products for the life science develop new applications. With our partners, sensitive, cost-effective mass spectrometry- sequencing libraries for comprehensive research and diagnostic markets. In our Life Bruker is enabling innovation in Life Sciences, based platform, the MassARRAY® System, mutation profi ling and immune repertoire Science Group, we build the industry leading routine pathology, microbiology and is used in fi elds such as cancer profi ling for characterization by NGS. Complemented solutions for oncology research, including molecular diagnostics. MALDI Tissuetyper solid tumors and liquid biopsies, inherited by a powerful suite of assay design and the highly sensitive Droplet Digital™ PCR allows measurements from FFPE tissue. c Program c c Program c genetic disease testing, pharmacogenetics, bioinformatics analysis software, Archer technology and our new technology for It is able to measure proteins, peptides, and clinical research. We are a leader FusionPlex®, VariantPlex® and Reveal single-cell sequencing, the ddSEQ™ Single- lipids, drugs, and metabolites. Detected ® Scientifi dedicated to enabling clinical laboratories ctDNA assays facilitate complex mutation Cell Isolator. compounds can be visualized as a fused Scientifi worldwide delivering targeted genomic identifi cation, and Immunoverse™ assays image. testing. enable quantitative profi ling of the expressed Bristol-Myers immune repertoire. Squibb CELEMICS Agilent Technologies Booth No. G17 Booth No. G4 Booth No. T13 Beckman Coulter USA Korea The Netherlands Booth No. T15+16 +1 609-302-3000 +82-2-6746-8067 +31 20 5472000 The Netherlands www.bms.com [email protected] [email protected] www.beckmancoulter.com www.celemics.com www.genomics.agilent.com/en/home.jsp Bristol-Myers Squibb is a global Beckman Coulter empowers the research biopharmaceutical company focused on Celemics, A Global Leader in NGS community with solutions that simplify and discovering, developing and delivering Target Enrichment kit st

Poster Exhibition Poster Agilent is a leader in life sciences, diagnostics improve results for complex biomedical innovative for patients with Celemics, the 1 NGS target enrichment Exhibition Poster and applied chemical markets. The testing. The SPRI-paramagnetic bead-based serious diseases. We are focused on helping kit manufacturer in both Asia and Europe, company provides laboratories worldwide reagents provide fast and effi cient isolation patients in disease areas including oncology, has secured itself in the global market as a with instruments, services, consumables, of nucleic acids from many sample types. cardiovascular, immunoscience and fi brosis. pioneer of Target Enrichment methodology applications and expertise, enabling Our Ampure XP is a gold standard in NGS Each day, our employees work together for and sample preparation for DNA sequencing customers to gain the insights they seek. applications. Our Biomek Systems automate patients – it drives everything we do. and genetic testing. From the Diagnostics and Research fi eld, applications in molecular biology resulting Agilent gives doctors a head start in the fi ght in a standardize workfl ow with increased against cancer and other diseases. Discuss productivity. your laboratory needs with an Agilent expert. Industry Partners Industry Partners

58 | AMP Europe 2018 AMP Europe 2018 | 59 Industry Partners Exhibitor Description Industry Partners Exhibitor Description

Covaris Epigenomics GC biotech BV Illumina Booth No. T2 Booth No. G3 Booth No. T18 Booth No. T9 UK USA The Netherlands UK +44 (0)845 872 0100 +1 415 637 1609 +31 (0)182 22 33 00 +44 8000126019

Congress Information Congress [email protected] [email protected] [email protected] [email protected] Information Congress www.covaris.com www.epigenomics.com www.gcbiotech.com www.illumina.com

Covaris is the recognized industry leader Epigenomics has two commercial products GC biotech sources the latest developments Illumina is a leading developer, manufacturer, for DNA fragmentation. Adaptive Focused – Epi proColon is the fi rst and only FDA- in automation and reagents for diagnostics and marketer of life science tools and Acoustics® (AFA™) is the gold standard for approved blood test for colon cancer and life science research from around integrated systems for large-scale analysis of shearing DNA and RNA in Next-Generation screening (CE in 2016) & Epi proLung is the world. We aim to help you take your genetic variation and function. Our customers Sequencing applications, without GC bias or intended for nodule adjudication for lung research to a higher level. GC biotech also include a broad range of academic, thermal-induced damage. Covaris Focused- cancer (CE in 2017). Both can be performed manufactures CleanNA. With CleanNA, GC government, pharmaceutical, biotechnology, ultrasonicators are recommended by all major on your RT PCR equipment. Also available biotech develops and manufactures magnetic and other leading institutions around c Program c c Program c NGS sequencing platform providers, and are is a DNA extraction/Bisulfi te conversion bead-based kits with a focus on high the globe. For further details please visit used by leading Genome Centers. pre-analytical kit (CE in 2018) for various throughput nucleic acid purifi cation. www.illumina.com. Scientifi applications. Scientifi Diatech GeneFirst Ltd LexaGene Pharmacogenetics ExScale Biospecimen Booth No. T17 Booth No. G9 Italy Solutions AB UK USA +39 0731 213249 Booth No. G13 +44 (0) 1865407400 +1 800 215 1824 [email protected] Sweden info@genefi rst.com [email protected] www.diatachpharmacogenetics.com +46 73 6289153 www.genefi rst.com www.lexagene.com [email protected] Diatech Pharmacogenetics supports its own www.exscalebio.com GeneFirst is a molecular diagnostics LexaGene is developing an on-site pathogen research efforts developing, producing and company working in cancer diagnostics using detection instrument, the LX6, that can commercializing pharmacogenetic tests CE ExScale is a Swedish company specializing liquid biopsy. We develop proprietary qPCR process six liquid samples at a time, returning IVD implemented in the personalised and in processes and know-how for nucleic acid and NGS technologies for cancer mutation results in about one hour. Using microfl uidics,

Poster Exhibition Poster , with priority focused extraction from human tissue specimens. detection. Our novel library preparation the instrument concentrates pathogens Exhibition Poster on the most invasive therapies: anti- With the business idea to market the Next method overcomes all limitations associated and then purifi es the DNA and RNA before cancer treatments. The kits developed by Generation Extraction technology, NGEx®, with the current technologies such as assembling and performing 22 qPCR tests. Diatech target to personalize both standard our mission is to help drive the advancement ineffi ciency, complex and low sensitivity. It Its open-access feature allows end users to and radiotherapy and of personalized cancer medicine and is suitable for sensitively detecting cancer load their own assays for customized genetic molecular targeted drugs, leading to higher contribute to improved management of biomarkers in plasma and other challenging testing. effi cacy and reduced . cancer patients and related research. materials. Industry Partners Industry Partners

60 | AMP Europe 2018 AMP Europe 2018 | 61 Industry Partners Exhibitor Description Industry Partners Exhibitor Description

MRC-Holland New England Oxford Gene Technology Philips Molecular Booth No. T11 Biolabs GmbH (OGT) Pathway Dx be drive stay The Netherlands Booth No. T4 INSPIRED DISCOVERY GENUINE Booth No. T14 Booth No. T8 +31 88 865 7200 Germany UK The Netherlands

Congress Information Congress [email protected] +49 69 305-23140 +44 1865 856823 www.philips.com/oncosignal Information Congress www.mlpa.com [email protected] [email protected] www.neb-online.de www.ogt.com Philips OncoSignal Molecular Pathway Multiplex Ligation-dependent Probe Diagnostics reveals the activity of the signal Amplifi cation (MLPA®) is the gold standard for New England Biolabs, Inc. is the industry Oxford Gene Technology (OGT) provides transduction pathways that drive tumor DNA copy number quantifi cation and is used leader in the discovery and production of world-class genetics research solutions. growth, having the potential to offer accurate worldwide to study both hereditary disorders enzymes for molecular biology applications OGT’s Cytocell®, CytoSure™ and SureSeq™ therapy response prediction for informed and tumours. MLPA can also be applied to and now offers the largest selection of range of fl uorescence in situ hybridisation personalized cancer treatment decisions. investigate the methylation status of DNA recombinant and native enzymes for genomic (FISH), microarray and next generation This is achieved by measuring mRNA sequences. Up to 60 DNA sequences can research. NEB continues to expand its sequencing (NGS) products deliver high- transcribed from target genes of the pathway c Program c c Program c be analysed in a single reaction in high- product offerings into areas related to PCR/ quality genetic analysis. OGT was recently transcription factors, and data interpretation throughput manner, with results being qPCR, sample preparation for Next-Gen-Seq, acquired (June 2017) by Sysmex Corporation with computational pathway models. Scientifi available within 24h. and RNA analysis. NEB is represented in (Sysmex), a Japanese in vitro diagnostic Scientifi Europe by subsidiaries. organisation expanding Sysmex’s life science Promega Corporation NanoString business and reinforcing its initiatives towards Booth No. T12 Technologies OncoDNA S.A. personalised medicine. USA Booth No. G1 Booth No. G10 +1 608 2744330 USA Belgium Oxford Nanopore [email protected] (888) 358-6266 +32 71 183500 Technologies Ltd. www.promega.com [email protected] [email protected] Booth No. T5 www.nanostring.com www.oncodna.com UK Promega Corporation provides innovative +44 845 0347900 solutions for forensics, life science, clinical NanoString is a life sciences company OncoDNA is a Belgian-based cancer [email protected] research, and molecular diagnostics. With focused on cancer research and diagnostics. theranostic company which aims to support www.nanoporetech.com a portfolio of more than 3,000 products,

Poster Exhibition Poster Proven in over 1,000 peer-reviewed oncologists in their treatment choices Promega has a breadth of solutions spanning Exhibition Poster publications, the nCounter® System can and/or help to monitor the evolution of Oxford Nanopore Technologies has the clinical laboratory’s workfl ow. Promega combine with 3D biology™ technology to cancer. OncoDNA solutions are based developed the world’s fi rst nanopore DNA is a trusted partner, with more than 35 years create novel biomarkers. The Prosigna® on a combination of the most relevant sequencer. The MinION is a portable, real- of manufacturing experience, to supply the Breast Cancer Prognostic Gene Signature and advanced technologies to shed light time, long-read, low-cost device designed robust and reliable solutions you need for Assay provides FDA 510(k)-cleared on the complex mechanisms that drive to bring easy biological analyses to anyone, your molecular assay. diagnostics with the nCounter Dx Analysis cancer development and contribute to whether in scientifi c research or real-world System. the knowledge applied to the fi ght against applications such as disease/pathogen cancer. surveillance, environmental monitoring, food chain surveillance, or microgravity biology. The GridION and PromethION devices serve users with larger projects or more samples. Industry Partners Industry Partners

62 | AMP Europe 2018 AMP Europe 2018 | 63 Industry Partners Exhibitor Description Industry Partners Exhibitor Description

QIAGEN SeraCare STEMCELL STRATEC Booth No. T19 Life Sciences Technologies Molecular GmbH Germany Booth No. G11 Booth No. T7 Booth No. G15 +49 2103 290 USA France Germany

Congress Information Congress [email protected] +1 508 244 6400 +33 (0)4 76 04 75 30 +49 30 9489 2901 Information Congress www.qiagen.com [email protected] [email protected] [email protected] www.seracare.com www.stemcell.com www.molecular.stratec.com QIAGEN is the leading global provider of Sample to Insight solutions to transform SeraCare is a leading partner to global At STEMCELL science is our foundation. As part of the STRATEC Group, STRATEC biological materials into valuable molecular IVD manufacturers and clinical testing Driven by our mission to advance scientifi c Molecular provides products for manual insights. Sample technologies isolate and laboratories. Our expanding portfolio of QC research globally, we offer more than 2,500 and automated DNA/RNA extraction from a process DNA, RNA and proteins from products and technologies for genomic tools and services supporting discoveries in broad variety of samples starting with sample blood, tissue and other materials. Assay diagnostics includes reference materials , tissue engineering, collection, stabilization and purifi cation. New technologies make these biomolecules for tumor sequencing, germline mutation , immunotherapy and disease products include kits for automated DNA c Program c c Program c visible and ready for analysis. Bioinformatics testing, NIPT, and infectious disease. Today, research. Inspired by knowledge, innovation extraction from FFPE tissue, cell-free DNA software and knowledge bases interpret data SeraCare is advancing data integration and quality, we are Scientists Helping isolation from liquid biopsy samples and Scientifi to report relevant, actionable insights. with products for better QC and regulatory Scientists. automated bisulfi te conversion on DNA. Scientifi compliance. Roche Diagnostics Stilla Technologies Thermo Fisher Booth No. T3 SOPHiA GENETICS Booth No. G18 Scientifi c USA Booth No. T1 FRANCE Booth No. T6 www.roche.com Switzerland +33 9 82 29 50 50 UK +41 21 694 10 60 [email protected] +44 141 814 6100 At Roche Diagnostics, our focus is to [email protected] www.stillatechnologies.com martha.hall@thermofi sher.com improve the lives of patients, from research www.sophiagenetics.com www.thermofi sher.com to lab tests to personalized healthcare; we Stilla Technologies focuses on accelerating touch the entire spectrum of diagnostics SOPHiA GENETICS is a health tech the development of next-generation genetic Thermo Fisher Scientifi c is the world leader users. Roche Diagnostics is a member of company which has developed SOPHiA tests by providing innovative instrumentation in serving science with revenues of 17 billion,

Poster Exhibition Poster the Roche Group, which is headquartered in Artifi cial Intelligence, the universal and for digital PCR. In 2016, Stilla Technologies and approximately 50,000 employees in Exhibition Poster Basel, Switzerland. innovative technology for clinical genomics. launched the Naica System, the fi rst and only 50 countries. Through our premier brands By facilitating the rapid adoption of genomic dPCR solution to offer 3-color multiplexing. – Thermo Scientifi c, Applied Biosystems, testing worldwide, turning data into Other key features of the system are Invitrogen, Fisher Scientifi c and Unity actionable clinical insights and facilitating the speed, simplicity and versatility of its Lab Services – we offer an unmatched knowledge sharing, we are democratizing workfl ow. combination of innovative technologies, Data-Driven Medicine to help save patients’ purchasing convenience and comprehensive lives around the world. support. Industry Partners Industry Partners

64 | AMP Europe 2018 AMP Europe 2018 | 65 Industry Partners Exhibitor Description

Twist Bioscience XIAMEN SPACEGEN Booth No. G19 CO., LTD. USA Booth No. G8 800-719-0671 China

Congress Information Congress [email protected] +86 592-7578317 www.twistbioscience.com [email protected] www.ispacegen.com At Twist Bioscience Corporation, we work in service of customers who are changing Xiamen Spacegen concerned with the the world for the better. Our innovative R&D, production and services of oncology silicon-based DNA Synthesis Platform precision medicine, provides the total solution provides precision at a scale that is otherwise products of automated molecular IVD kits for unavailable to our customers. Our platform early screening, disease diagnosis, individual technologies overcome ineffi ciencies and drug selection and effi cacy monitoring. c Program c enable cost-effective, rapid, precise, high- Spacegen focus on gene mutation throughput synthesis and sequencing, detections(BRCA1/2, EGFR, KRAS, BRAF

Scientifi providing both the quality and quantity of etc) based on Next Generation Sequencing, the tools they need to rapidly realize the Real Time PCR and other technology opportunity ahead. platforms.

Imprint

Scientifi c Organization Association for Molecular Pathology (AMP) 9650 Rockville Pike Bethesda, MD 20814 United States of America

Legal Organizer (PCO) MCI Deutschland GmbH Poster Exhibition Poster MCI | Germany – Berlin Markgrafenstrasse 56 10117 Berlin, Germany T: +49 30 2045937 F: +49 30 2045950 [email protected] amp-europe-congress.com

VAT ID number: DE 114406202, Local Court Berlin-Charlottenburg, HRB 100620B Managing Directors: Andreas Laube, Thomas Wüthrich

Editorial Deadline April 12, 2018

All information is supplied without liability and is subject to change. Industry Partners

66 | AMP Europe 2018 Bristol-Myers Squibb is Searching for Ways to Improve Patient Outcomes Through Emerging I-O Biomarker Research We’re committed to identifying Immuno-Oncology (I-O) biomarkers that can help inform personalized treatment plans for patients.

Learn more about our mission to connect the right patients with the right I-O therapy at Booth G17.

References: 1. Ma W et al. J Hematol Oncol. 2016;9(1):47. 2. Gibney GT et al. Lancet Oncol. 2016;17(12):e542-e551. 3. Chen DS, Mellman I. Nature. 2017;541(7637):321-330.

At the Forefront of Immuno-Oncology Research

Tumor Eff ector cell

© 2018 Bristol-Myers Squibb Company. All rights reserved. IONL18NP01085 03/18